Unterberg Capital’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Unterberg Capital’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,667	Closed	-$976K	–	23
2018 Q2	$976K	Hold	2,667	–	–	1.16%	20
2018 Q1	$788K	Buy	2,667 +1,000	+60%	+$295K	0.92%	26
2017 Q4	$698K	Buy	+1,667	New	+$596K	0.85%	27

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Unterberg Capital's EIGR Position: Q3 2018 in Review

Unterberg Capital sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2018, closing a stake of 2,667 shares — an estimated $976K sold.

Unterberg Capital first reported a position in EIGR in Q4 2017 and held it in 3 quarters. The position peaked at $976K in Q2 2018. 53 funds tracked by Wall St. Rank hold EIGR as of Q3 2018.

Unterberg Capital reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Unterberg Capital sold 2,667 Eiger BioPharmaceuticals, Inc. shares in Q3 2018, an estimated $976K.
Unterberg Capital first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
Unterberg Capital's Eiger BioPharmaceuticals, Inc. position peaked at $976K in Q2 2018.
53 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2018.

Based on Unterberg Capital's 13F filing for Q3 2018, filed 24 Oct 2018.